Schulman E.,Lankenau Institute for Medical Research
Headache | Year: 2013
Refractory migraine has long been a challenge to all headache specialists. This subgroup of migraine patients experience disability and impaired quality of life, despite optimal treatment. This article reviews the proposed definitions and epidemiology of refractory migraine, as well as the pathophysiology that may contribute to the genesis of this disorder. Aspects of treatment, including pharmacological, complementary/adjunct, and invasive approaches, are reviewed. Comorbid factors, medication overuse, potential pitfalls to treatment, and areas for future investigation are highlighted. © 2013 American Headache Society.
Lankenau Institute For Medical Research | Date: 2014-03-27
Compositions and methods for the measuring toxicity, antioxidant capacity, and oxidative stress are provided.
Lankenau Institute For Medical Research | Date: 2013-11-19
Lankenau Institute For Medical Research | Date: 2013-02-26
Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.
Lankenau Institute For Medical Research and Aminex Therapeutics | Date: 2013-02-20
This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (PBT) for relieving tumor-induced suppression of the patients immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vectors ability to evade an immune reaction. This therapeutic approach is equally applicable to disease states whereby immune system suppression by polyamines has been demonstrated including; bacterial infections, parasitic infections including malaria and typanosomiasis, viral infections, peptic ulcers and gastric cancer due to